Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Nashville, TN
SEC filing record 1 source field available
Fiscal year end
31 December
Revance Therapeutics, Inc. has filed 947 SEC EDGAR filings since 23 Dec 2009

SEC filing history

Showing 901-925 of 946 matching filings.

Per page
25
Current page
37
4

FORM 4 SUBMISSION

Filing date
11 Feb 2014
Reporting date
11 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
11 Feb 2014
Reporting date
11 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
11 Feb 2014
Reporting date
11 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
11 Feb 2014
Reporting date
11 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
11 Feb 2014
Reporting date
11 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
11 Feb 2014
Reporting date
11 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
CT ORDER File 333-193154

CT ORDER filing

Filing date
06 Feb 2014
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
424B4 File 333-193154

424B4

Filing date
06 Feb 2014
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-193154

EFFECT filing

Filing date
05 Feb 2014
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
05 Feb 2014
Reporting date
05 Feb 2014
SEC evidence
Open document Open filing
Next action
Verify source filing
S-1MEF File 333-193778

FORM S-1MEF

Filing date
05 Feb 2014
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CERTNAS File 001-36297

AUTO-GENERATED PAPER DOCUMENT

Filing date
04 Feb 2014
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CORRESP

CORRESP filing

Filing date
04 Feb 2014
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-A12B File 001-36297

8-A12B

Filing date
04 Feb 2014
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .